4.5 Article

Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 4, Issue 3, Pages 353-357

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/ml300467n

Keywords

WDR5; MLL; SET1 methyltransferase complex; peptide binding site; small molecule antagonists

Funding

  1. Canadian Institutes for Health Research, Genome Canada [1097737]
  2. Canadian Foundation for Innovation
  3. Ontario Innovation Trust
  4. Ontario Ministry for Research and Innovation
  5. Wellcome Trust
  6. AbbVie
  7. Eli Lilly Canada
  8. GlaxoSmithKline
  9. Novartis
  10. Pfizer
  11. Takeda
  12. Government of Ontario through the Ontario Ministry of Economic Development and Innovation

Ask authors/readers for more resources

The WD40-repeat protein WDRS plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K-dis = 7 mu M), leading to identification of more potent antagonist 47 (K-dis = 0.3 mu M).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available